Literature DB >> 16416446

Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons--possible involvement of endogenous kynurenic acid.

Lilly Schwieler1, Sophie Erhardt, Linda Nilsson, Klas Linderholm, Göran Engberg.   

Abstract

Kynurenic acid (KYNA) is an endogenous glutamate-receptor antagonist with a preferential action at the glycine-site of the NMDA-receptor. In the present in vivo study, the importance of brain KYNA to modulate the activity of dopamine (DA) neurons in the ventral tegmental area (VTA) was analyzed by utilizing the decrease in brain KYNA formation induced by the cyclooxygenase (COX)-2 inhibitor parecoxib. A reduction in brain KYNA concentration (39-44%) by parecoxib (25 mg/kg, i.v., 1 h or, i.p., 3.5 h) was associated with a decreased firing rate and burst firing activity. In concordance, an increase in brain KYNA concentration (150-300%), induced by the COX-1 inhibitor indomethacin (50 mg/kg, i.v., 1 h or, i.p., 3.5 h), produced opposite effects, that is, increased firing rate and burst firing activity. The decrease and increase in neuronal firing of VTA DA neurons by the COX-inhibitors was reversed by L-701,324 (antagonist at the NMDA-glycine site; 0.06-2 mg/kg, i.v.) and by D-cycloserine (partial agonist at the NMDA-glycine site; 2-32 mg/kg, i.v.), respectively. In addition, the parecoxib-induced decrease in firing rate and burst firing activity was effectively blocked by pretreatment with kynurenine (5 mg/kg, i.p., 30 min), the immediate precursor of KYNA. Present results suggest that the action of COX-inhibitors on the firing of VTA DA neurons are linked to their effects on KYNA formation and that endogenous KYNA is tonically modulating the neuronal activity of VTA DA neurons. Such a modulatory action of KYNA should be of importance for the functioning of mesocorticolimbic DA pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16416446     DOI: 10.1002/syn.20241

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  17 in total

1.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Authors:  Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt
Journal:  Schizophr Bull       Date:  2010-08-20       Impact factor: 9.306

Review 2.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

Review 3.  Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later.

Authors:  Gregory F Oxenkrug
Journal:  Isr J Psychiatry Relat Sci       Date:  2010       Impact factor: 0.481

4.  Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders.

Authors:  Gregory F Oxenkrug
Journal:  J Neural Transm (Vienna)       Date:  2010-09-02       Impact factor: 3.575

5.  Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder.

Authors:  Sara K Olsson; Martin Samuelsson; Peter Saetre; Leif Lindström; Erik G Jönsson; Conny Nordin; Göran Engberg; Sophie Erhardt; Mikael Landén
Journal:  J Psychiatry Neurosci       Date:  2010-05       Impact factor: 6.186

6.  Exposure to kynurenic acid during adolescence produces memory deficits in adulthood.

Authors:  Cynthia O Akagbosu; Gretchen C Evans; Danielle Gulick; Raymond F Suckow; David J Bucci
Journal:  Schizophr Bull       Date:  2010-12-20       Impact factor: 9.306

7.  Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.

Authors:  Maximilian Tufvesson-Alm; Lilly Schwieler; Robert Schwarcz; Michel Goiny; Sophie Erhardt; Göran Engberg
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

8.  Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice.

Authors:  Sara K Olsson; Markus K Larsson; Sophie Erhardt
Journal:  J Neural Transm (Vienna)       Date:  2011-09-09       Impact factor: 3.575

9.  The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons?

Authors:  Elyssa B Margolis; Hagar Lock; Gregory O Hjelmstad; Howard L Fields
Journal:  J Physiol       Date:  2006-09-07       Impact factor: 5.182

Review 10.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.